Centrient Pharmaceuticals (PRIVATE.CENTRIENT)

Overall impact
B (62)

Commentary

Centrient Pharmaceuticals is a strong overall performer. With a 'B' rating of 61.5 for overall impact (66th percentile compared to all companies), Centrient Pharmaceuticals ranks 104th out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 100 others, and ahead of Evolus, Oyster Point Pharma, Aurobindo Pharma and 47 others. On top material causes for Centrient Pharmaceuticals's industry (Pharmaceuticals), Centrient Pharmaceuticals performs well in Technology Innovation (94.8 score), Child and Maternal Health (91.4), Access to Affordable Healthcare (95.4) and 1 other cause where it received an 'A' score and performs poorly in Reduced Use of tobacco (29.5 score), Reduced Waste (33.4), Humane Treatment of Animals (37.1) and 1 other cause where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.CENTRIENT
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1868
Employees
2,200
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Netherlands
Share classes
PRIVATE.CENTRIENT
Description
Manufacturer of sustainable antibiotics, next-generation statins and antifungals based in Rijswijk, Netherlands. The company is engaged in the production and commercialization of sustainable antibiotics and produces intermediates, active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), enabling clients to meet their sustainable and accessible pharmaceutical needs.
Material causes
Ethos considers the following causes material for Centrient Pharmaceuticals, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.